SEP 01, 2016 4:58 AM PDT

Drug Clears Toxic Protein Clusters in Alzheimer's Brain

WRITTEN BY: Xuan Pham
The beloved actor Gene Wilder died earlier this week from complications of Alzheimer’s disease. He was one of the tens of thousands of people who succumb to the disease, according to the Centers for Disease Control and Prevention.
 
But there’s some hope peeking through the grim statistics of this disease. Scientists recently announced highly promising results of a drug that purportedly can erase the toxic protein clumps in the Alzheimer brain.
 
Promising results for experimental Alzheimer drug | Image: pexels.com
The drug, known as aducanumab, targets the amyloid beta plaques in the brains of animal models, and now also in human clinical trials. As this drug progresses to Phase 3 to test efficacy in a larger group of patients, researchers are hopeful it will become the first drug to actually reverse Alzheimer pathology.
 
Amyloid plaque clumps (yellow) in the brainAlzheimer’s disease is pathologically defined with the presence of amyloid beta protein clumps in the brain. These are toxic to neurons and interfere with memory, cognition, and other normal functions of the brain. The CDC estimated 85,000 people died from Alzheimer’s disease in 2015; however, this number is believed to be an underestimate, as many deaths may not be correctly attributed to Alzheimer’s.
 
Aducanumab is an immune compound that appears to stimulate the body to remove the toxic amyloid clumps. In the latest study, scientists split 165 patients with mild Alzheimer’s disease into two groups: those who received aducanumab and those who received a placebo. This was done for 1 year, with the intent on demonstrating that the drug was safe to take.
 
Indeed, researchers found encouragement beyond safety. Through analyzing brain scans, the team found that patients treated aducanumab had less amyloid plaques than those treated with the placebo.
 
"After one year, you can see no red on the image, meaning the amyloid has almost completely
disappeared," said Dr. Roger Nitsch, a co-author of the study and the director of the Institute for Regenerative Medicine at the University of Zurich.
 
In addition, there was a direct correlation between dose and effect – the higher the dose, the greater the clearance of the toxic protein clumps. Notably, however, the higher dosages were also associated with more side effects.
 
Though the purpose of the study was to establish safety, the team did carry out some memory tests with some promising results. "We believe that's a hint of efficacy," study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen,
 
"We're encouraged that, there appeared to be a slowing of cognitive decline at a dose-dependent manner, and also a dose-dependent slowing in functional decline," said study co-author Dr. Stephen Salloway.
 
The next phase of the study will definitively answer whether aducanumab holds cognitive benefits for Alzheimer’s patients. A total of 2,700 patients are slated to be enrolled in this next phase, which will be an international effort involving North America, Europe, and Asia.
 
 
Additional sources: BBC, Nature News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 20, 2021
Clinical & Molecular DX
Stressed Out Pregnant Mothers More Likely to Have Girls
APR 20, 2021
Stressed Out Pregnant Mothers More Likely to Have Girls
Scientists from the University of Granada used hair samples to monitor cortisol in a cohort of over 100 pregnant women a ...
MAY 18, 2021
Genetics & Genomics
Library Prep Methods for SARS-CoV-2 Sequencing: a Summary
MAY 18, 2021
Library Prep Methods for SARS-CoV-2 Sequencing: a Summary
As the SARS-CoV-2 virus continues to mutate, rapid sequencing of COVID-19-positive samples is more critical than ever. N ...
MAY 24, 2021
Clinical & Molecular DX
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
MAY 24, 2021
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
Over 1.5 billion vaccine doses have been administered worldwide, but SARS-CoV-2 variants are now threatening efforts to ...
JUN 02, 2021
Genetics & Genomics
A Genetic Form of ALS is Discovered
JUN 02, 2021
A Genetic Form of ALS is Discovered
Some medical mysteries have become much easier to solve because of advanced genetic techniques that have enabled researc ...
JUL 27, 2021
Clinical & Molecular DX
Thumb-Sized Device Tells You if Your Breath Stinks
JUL 27, 2021
Thumb-Sized Device Tells You if Your Breath Stinks
People generally can’t smell their own breath. So, for individuals with halitosis—or bad breath—friend ...
AUG 04, 2021
Clinical & Molecular DX
Fear of Smells Could Help Diagnose Migraines in Kids
AUG 04, 2021
Fear of Smells Could Help Diagnose Migraines in Kids
  A new study suggests the intense dislike of pungent smells and odors could be a diagnostic marker for migraines a ...
Loading Comments...